Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723883 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL25827165 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL22604289 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL14194007 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL4864303 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL20730512 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL20729523 | 1.00 | HTR2A (0.39) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL24299478 | 0.86 | HTR2A (0.30) | HTR2AADRA1A | |
| SCHEMBL14194246 | 0.86 | ALB (0.34) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C | |
| SCHEMBL4869663 | 0.86 | ALB (0.34) | HTR2AADRA1AALDH1A1L3MBTL1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809156-B1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | UNIV TEXAS (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9533973-B2 | Allosteric modulators of 5-hydroxytryptamine 2C receptor (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140336375-A1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336375-A1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2013086266-A2 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336375-A1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | HTR2C, HTR2A, HTR3B | HTR2A 2/4885ADRA1A 211/4885ALDH1A1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.